

WD

Gp/643/8
Box Seq.
PATENT

Attorney Docket No.: A-67501/DJB/TAL/DAV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of:

GOETZL et al.

Serial No. 09/274,752

Filed: March 23, 1999

For: HUMAN POLYPEPTIDE
RECEPTORS FOR LYSO-
PHOSPHOLIPIDS AND SPHING-
OLIPIDS AND NUCLEIC ACIDS
ENCODING THE SAME

) Examiner: Harris, A.

) Group Art Unit: 1643

OCT 18 1999

TECH CENTER 1600/2900

RECEIVED

OCT 15 1999

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on:

Dated: 10-8-99

Signed: Christine P. Peters

Christine P. Peters

TRANSMITTAL OF RESPONSE TO COMMUNICATION
AND NOTICE TO COMPLY

BOX SEQUENCE LISTING

Assistant Commissioner
for Patents
Washington, DC 20231

Sir:

In response to the Office Communication and accompanying Notice
to Comply With Requirements for Patent Applications Containing Nucleotide

10/14/1999 SLUW6 00000073 09274752 55.00 0P
01 FC:215

Serial No.: 09/274,752
Filed: March 23, 1999

Sequence and/or Amino Acid Sequence Disclosures dated August 11, 1999,
enclosed are the following documents:


1. Paper copy of SEQUENCE LISTING;
2. Computer readable form of Sequence Listing;
3. Preliminary Amendment;
4. Copy of Notice to Comply;
5. Petition for Extension of Time;
6. Check in the amount of \$55.00

The Commissioner is authorized to charge any additional fees
which may be required, or credit any overpayment to Deposit Account No. 06-1300
(Our Order No. A-67501/DJB/TAL/DAV).

A duplicate copy of this sheet is enclosed.


Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP



Todd A. Lorenz
Reg. 39,754

Four Embarcadero Center
Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
(627678)



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

PD

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/274,752 03/23/99 GOETZL E A-67501/DJB/

HM12/0811
FLEHR HOHBACH TEST ALBRITTON & HERBERT
FOUR EMBARCADERO CENTER
SUITE 3400
SAN FRANCISCO CA 94111-4187

EXAMINER

HARRIS, A

ART UNIT	PAPER NUMBER
----------	--------------

1642

4

DATE MAILED:

08/11/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

File A-67501 Atty DJB/TAL
Due Date 9/11/99
Type Response Letter Refs -



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
1642	4

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.
2. Any inquiry concerning this communication should be directed to Examiner Alana Harris, Art Unit 1642, whose telephone number is (703)306-5880.
3. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed at the bottom of the Notice to Comply.
4. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Alana Harris
Alana Harris, Ph.D.
Patent Examiner, Group 1642

Nancy A Johnson
Nancy A Johnson
Primary Examiner

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

OPEN HOUSE PROGRAM

B70

Technology Center
August 23-25, 1999

Location: Crystal Ballroom
1999 Jefferson Davis Highway
Arlington, VA 22202

Cost: \$70 (Includes: program, lunch on 8/24, reception on 8/25)

Program Includes:

- Patent Operations Issues
- Design Issues
- Tours of the Technology Center
- Demonstrations of Automation Tools Including PatentIn
- Panels of SPEs on current topics

• Patent Quality Update
• Biotech Policy
• BIO Strategic Planning
• Patent Automation Initiatives
• Town Hall Meeting
• Luncheon Speech by Q. Todd Dickinson Acting Commissioner of Patents and Trademarks

For more information or to register by phone, call 703-308-1234; your payment can be made by credit card or check made payable to "BIO"